Sign inGet started

EASTLAND JULIA MARIE

Insider CIK 1500189 · DVAX Director · ONTY CFO & VP, CORP. DEVELOPMENT · LNTH Director · GRAY Director · HARP President and CEO, Director · ZNTL CEO & President, Director

Track record PRO

XXXX$█.██M██+██%
XXXX$█.██M██+██%
XXXX$█.██M██+██%
Track record
See how this insider's past purchases performed 30 and 90 days later, and a conviction score on each buy.
Upgrade to Pro · $99/yearAlready Pro? Log in

Trades across companies

TickerCodeTradeFiledSharesPriceValueOwned after
LNTH Lantheus Holdings, Inc. A Award2026-05-142026-05-184,137— $08,019SEC↗
ZNTL Zentalis Pharmaceuticals, S Sale2026-02-092026-02-10889$2.39 $2.1K79,133SEC↗
ZNTL Zentalis Pharmaceuticals, S Sale2026-02-062026-02-107,866$2.43 $19.1K80,022SEC↗
ZNTL Zentalis Pharmaceuticals, A Award deriv2026-01-082026-01-09775,000— $0775,000SEC↗
LNTH Lantheus Holdings, Inc. A Award deriv2025-05-142025-05-164,543— $04,543SEC↗
LNTH Lantheus Holdings, Inc. A Award2025-05-142025-05-162,537— $03,882SEC↗
ZNTL Zentalis Pharmaceuticals, A Award deriv2025-02-032025-02-0559,388— $059,388SEC↗
ZNTL Zentalis Pharmaceuticals, A Award2025-02-032025-02-0559,388— $087,888SEC↗
ZNTL Zentalis Pharmaceuticals, P Buy2025-01-312025-02-0428,500$1.73 $49.3K28,500SEC↗
ZNTL Zentalis Pharmaceuticals, A Award deriv2024-12-022024-12-033,028,800— $03,028,800SEC↗
LNTH Lantheus Holdings, Inc. A Award deriv2024-09-102024-09-122,506— $02,506SEC↗
LNTH Lantheus Holdings, Inc. A Award2024-09-102024-09-121,345— $01,345SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award deriv2024-05-232024-05-2822,500— $022,500SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award2024-05-232024-05-285,357— $016,071SEC↗
HARP Harpoon Therapeutics, Inc. D To issuer deriv2024-03-112024-03-1140,759— $00SEC↗
HARP Harpoon Therapeutics, Inc. D To issuer deriv2024-03-112024-03-112,765— $00SEC↗
HARP Harpoon Therapeutics, Inc. A Award2024-03-112024-03-1131,250— $0269,381SEC↗
HARP Harpoon Therapeutics, Inc. D To issuer2024-03-112024-03-11269,381— $00SEC↗
HARP Harpoon Therapeutics, Inc. A Award2024-01-072024-01-09178,500— $0232,003SEC↗
HARP Harpoon Therapeutics, Inc. A Award2023-11-262023-11-2850,000— $053,503SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award deriv2023-05-262023-05-3122,500— $022,500SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award2023-05-262023-05-315,357— $010,714SEC↗
GRAY CalciMedica, Inc. D To issuer deriv2023-03-232023-03-271,429— $00SEC↗
GRAY CalciMedica, Inc. D To issuer2023-03-232023-03-271,429— $01,429SEC↗
HARP Harpoon Therapeutics, Inc. A Award deriv2023-01-242023-01-26407,600— $0407,600SEC↗
GRAY GRAYBUG VISION, INC. A Award deriv2022-06-022022-06-0320,000— $020,000SEC↗
GRAY GRAYBUG VISION, INC. A Award deriv2022-06-022022-06-0320,000— $020,000SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award deriv2022-05-262022-05-2722,500— $022,500SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award deriv2022-05-262022-05-275,357— $05,357SEC↗
HARP Harpoon Therapeutics, Inc. A Award deriv2021-11-082021-11-09350,000— $0350,000SEC↗
GRAY GRAYBUG VISION, INC. A Award deriv2021-06-022021-06-0412,500— $012,500SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award deriv2021-05-282021-06-0225,000— $025,000SEC↗
HARP Harpoon Therapeutics, Inc. A Award deriv2021-05-042021-05-0710,167— $010,167SEC↗
HARP Harpoon Therapeutics, Inc. A Award deriv2021-05-042021-05-1410,167— $010,167SEC↗
GRAY GRAYBUG VISION, INC. A Award deriv2020-09-242020-09-2825,000— $025,000SEC↗
DVAX DYNAVAX TECHNOLOGIES CORP A Award deriv2020-07-172020-07-2150,000— $050,000SEC↗
HARP Harpoon Therapeutics, Inc. A Award deriv2020-05-282020-06-0110,167— $010,167SEC↗
HARP Harpoon Therapeutics, Inc. A Award deriv2019-06-032019-06-0510,167— $010,167SEC↗
HARP Harpoon Therapeutics, Inc. A Award deriv2019-02-072019-03-295,907— $05,907SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-136,667— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1316,500— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-138,334— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-138,334— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1325,000— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-13199,000— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-138,334— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1311,300— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1375,000— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1351,200— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1350,000— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1341,667— $00SEC↗
CASC Cascadian Therapeutics, In D To issuer deriv2018-03-092018-03-1316,667— $00SEC↗
CASC Cascadian Therapeutics, In U Tender2018-03-092018-03-135,237— $00SEC↗
CASC Cascadian Therapeutics, In A Award deriv2018-02-012018-02-02199,000— $0199,000SEC↗
CASC Cascadian Therapeutics, In M Exercise deriv2018-01-112018-01-162,825— $08,475SEC↗
CASC Cascadian Therapeutics, In M Exercise2018-01-112018-01-162,825— $06,160SEC↗
CASC Cascadian Therapeutics, In F Tax w/h2018-01-112018-01-16923$3.92 $3.6K5,237SEC↗
CASC Cascadian Therapeutics, In A Award deriv2017-09-182017-09-2016,500— $016,500SEC↗
CASC Cascadian Therapeutics, In A Award deriv2017-09-182017-09-2075,000— $075,000SEC↗
CASC Cascadian Therapeutics, In A Award deriv2017-01-112017-01-1311,300— $011,300SEC↗
CASC Cascadian Therapeutics, In A Award deriv2017-01-112017-01-1351,200— $051,200SEC↗
ONTY Oncothyreon Inc. A Award deriv2016-05-172016-05-19300,000— $0300,000SEC↗
ONTY Oncothyreon Inc. A Award deriv2015-09-242015-09-28250,000— $0250,000SEC↗
ONTY Oncothyreon Inc. A Award deriv2014-12-162014-12-16100,000— $0100,000SEC↗
ONTY Oncothyreon Inc. A Award deriv2013-12-122013-12-16150,000— $0150,000SEC↗
ONTY Oncothyreon Inc. A Award deriv2012-12-122012-12-1450,000— $050,000SEC↗